<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05127434</url>
  </required_header>
  <id_info>
    <org_study_id>mRNA-1345-P301</org_study_id>
    <nct_id>NCT05127434</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age</brief_title>
  <official_title>A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults ≥60 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ModernaTX, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ModernaTX, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the safety and tolerability of mRNA-1345&#xD;
      vaccine and to demonstrate the efficacy of a single dose of mRNA-1345 vaccine in the&#xD;
      prevention of a first episode of RSV-associated lower respiratory tract disease (RSV-LRTD) as&#xD;
      compared with placebo from 14 days postinjection through 12 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted in 2 phases: Phase 2 and Phase 3. In the Phase 2 segment, between&#xD;
      400 and 2,000 participants will be randomly assigned to receive a single injection of either&#xD;
      mRNA-1345 vaccine at the selected dose or placebo in a 1:1 randomization ratio.&#xD;
&#xD;
      In the Phase 3 segment, between 32,000 and 33,600 participants will be randomly assigned to&#xD;
      receive a single injection of either mRNA-1345 vaccine at the selected dose or placebo in a&#xD;
      1:1 randomization ratio.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 12, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs) up to 7 Days Postinjection</measure>
    <time_frame>Up to 7 days postinjection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Unsolicited Adverse Events (AEs) up to 28 Days Postinjection</measure>
    <time_frame>Up to 28 days postinjection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Medically Attended AEs (MAAEs), Adverse Events of Special Interests (AESIs), Serious Adverse Events (SAEs), and AEs Leading to Withdrawal up to 24 Months Postinjection</measure>
    <time_frame>Up to 24 months postinjection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vaccine Efficacy (VE) of mRNA-1345 to Prevent a First Episode of RSV-LRTD within the Period of 14 Days Postinjection up to 12 Months Postinjection</measure>
    <time_frame>14 days postinjection up to 12 months postinjection</time_frame>
    <description>VE of mRNA-1345 to prevent reverse transcription polymerase chain reaction (RT-PCR) confirmed protocol-defined RSV-LRTD, defined as 100*(1-RR), where RR is the ratio of attack rates in the mRNA-1345 group and the placebo group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>VE of mRNA-1345 to Prevent a First Episode of RSV-Associated Acute Respiratory Disease (RSV-ARD) within the Period of 14 Days Postinjection up to 12 Months Postinjection</measure>
    <time_frame>14 days postinjection up to 12 months postinjection</time_frame>
    <description>VE of mRNA-1345 to prevent RT-PCR confirmed protocol-defined RSV-ARD, defined as 100*(1-RR), where RR is the ratio of attack rates in the mRNA-1345 group and the placebo group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VE of mRNA-1345 to Prevent Hospitalizations Associated with RSV-ARD or RSV-LRTD within the Period of 14 Days Postinjection up to 12 Months Postinjection</measure>
    <time_frame>14 days postinjection up to 12 months postinjection</time_frame>
    <description>VE of mRNA-1345 to prevent RT-PCR confirmed protocol-defined RSV-ARD or RSV-LRTD, defined as 100*(1-RR), where RR is the ratio of attack rates in the mRNA-1345 group and the placebo group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer (GMT) of Serum RSV Neutralizing and Binding Antibodies (Abs)</measure>
    <time_frame>Baseline and 1, 6, 12, 18, and 24 months postinjection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold-Rise of Postbaseline/Baseline Ab Titers</measure>
    <time_frame>Baseline and 1, 6, 12, 18, and 24 months postinjection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with ≥4-fold Increases in Ab Titers from Baseline</measure>
    <time_frame>Baseline and 1, 6, 12, 18, and 24 months postinjection</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">34000</enrollment>
  <condition>Respiratory Syncytial Virus</condition>
  <arm_group>
    <arm_group_label>mRNA-1345</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single injection of mRNA-1345 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single injection of mRNA-1345 matching-placebo on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% sodium chloride (normal saline) injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mRNA-1345</intervention_name>
    <description>Sterile liquid for injection</description>
    <arm_group_label>mRNA-1345</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Adults ≥ 60 years of age who are primarily responsible for self-care and activities of&#xD;
             daily living. Participants may have one or more chronic medical diagnoses&#xD;
             (specifically chronic heart failure [CHF] and chronic obstructive pulmonary disease&#xD;
             [COPD]), but should be medically stable as assessed by the following criteria: absence&#xD;
             of changes in medical therapy within 1 month due to treatment failure or toxicity;&#xD;
             absence of medical events qualifying as SAEs within 1 month of the planned study&#xD;
             injection on Day 1; and absence of known, current, and life-limiting diagnoses, which&#xD;
             could continue for the duration of the primary efficacy period (12 months from study&#xD;
             injection on Day 1) and which, in the opinion of the investigator, would make&#xD;
             completion of the protocol unlikely.&#xD;
&#xD;
          -  Body mass index from ≥18 kilograms (kg)/square meter (m^2) to ≤35 kg/m^2.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Participation in another clinical research study where participant has received an&#xD;
             investigational product (drug/biologic/device) within 45 days before the planned date&#xD;
             of the Day 1 vaccination.&#xD;
&#xD;
          -  Prior participation in research involving receipt of any investigational RSV product&#xD;
             (drug/biologic/device).&#xD;
&#xD;
          -  History of a serious reaction to any prior vaccination or Guillain-Barré syndrome&#xD;
             within 6 weeks of any prior influenza immunization.&#xD;
&#xD;
          -  Received or plans to receive any non-study vaccine within 28 days before or after the&#xD;
             Day 1 study injection. The exceptions are seasonal influenza vaccines, pneumococcal&#xD;
             vaccines, or authorized or approved vaccines for the prevention of COVID-19&#xD;
             (regardless of type of vaccine), which are not permitted within 14 days before or&#xD;
             after the Day 1 study injection. Efforts should be made to space study injection and&#xD;
             COVID-19 vaccination by at least 7 and preferably 14 days, but COVID-19 vaccination&#xD;
             should not be delayed.&#xD;
&#xD;
        Other inclusion and/or exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Moderna Clinical Trials</last_name>
    <phone>877-913-3286</phone>
    <email>clinicaltrials@modernatx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Paradigm Research</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velocity Clinical Research, San Diego</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wr-Pri, Llc</name>
      <address>
        <city>Los Alamitos</city>
        <state>California</state>
        <zip>90720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wr-Pri, Llc</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FOMAT Medical Research - FOMAT - HyperCore - PPDS</name>
      <address>
        <city>Oxnard</city>
        <state>California</state>
        <zip>93030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jackonsville Center for Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palm Beach Research - ClinEdge - PPDS</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site Partners - Winter Park - HyperCore -PPDS</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IACT Health - Roswell - IACT - HyperCore - PPDS</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WR-Mount Vernon Clinical Research, LLC</name>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research- Savannah, GA</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East West Medical Research Institute</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velocity Clinical Research, Valparaiso</name>
      <address>
        <city>Valparaiso</city>
        <state>Indiana</state>
        <zip>46383</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research - Sioux City</name>
      <address>
        <city>Sioux City</city>
        <state>Iowa</state>
        <zip>51106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johnson County Clin-Trials</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark Research - Metairie - HyperCore - PPDS</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research- Rockville, MD</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20854</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research- Grand Island, NE</name>
      <address>
        <city>Grand Island</city>
        <state>Nebraska</state>
        <zip>68803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research- Lincoln, NE</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research, Binghamton, NY</name>
      <address>
        <city>Binghamton</city>
        <state>New York</state>
        <zip>13901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research- Endwell, NY</name>
      <address>
        <city>Endwell</city>
        <state>New York</state>
        <zip>13760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Institute for Clinical Research</name>
      <address>
        <city>Fayetteville</city>
        <state>North Carolina</state>
        <zip>28303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CTI Clinical Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tekton Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DM Clinical - Humble</name>
      <address>
        <city>Humble</city>
        <state>Texas</state>
        <zip>77338</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ACRC Trials - Hunt - PPDS</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas, LLC - HyperCore - PPDS</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DM Clinical - Tomball</name>
      <address>
        <city>Tomball</city>
        <state>Texas</state>
        <zip>77375</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velocity Clinical Research, Salt Lake City</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 9, 2021</study_first_submitted>
  <study_first_submitted_qc>November 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Viral Diseases</keyword>
  <keyword>Messenger RNA</keyword>
  <keyword>Moderna</keyword>
  <keyword>mRNA-1345</keyword>
  <keyword>Respiratory syncytial virus</keyword>
  <keyword>Safety</keyword>
  <keyword>Vaccines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

